GENE ONLINE|News &
Opinion
Blog

2018-10-05| Startups

Cambridge startup, GO Therapeutics make $195 million deal with Roche

by Rajaneesh K. Gopinath
Share To

This agreement grants Roche exclusive license for antibodies generated against novel cancer-specific targets and to develop a new glycotargeting bispecific antibody.

By Rajaneesh K Gopinath

GO Therapeutics Inc. (GO), an immuno-oncology startup company headquartered at Cambridge was founded in 2014. It applies new advances in glycoproteomics to develop potent, yet toxic free cancer therapeutics that are antibody-based. On October 2nd, the company announced that it has entered into a license agreement with Roche. This collaboration would facilitate the entry of its drug into the clinic by 2020. According to this agreement, Roche will pay GO $9 million upfront and the remaining $186 million in milestone payments. On top of this, GO would also receive royalties on any future product sales.

Constantine Theodoropulos, the chief executive officer of GO Therapeutics expressed his excitement over the deal. “We are excited about this collaboration to develop an innovative immune-redirected therapy to potentially improve the lives of patients suffering from cancer in the future,” he said in a statement. “GO’s glycoprotein targeting platform opens an exciting class of tumor-specific antigens that can help widen the therapeutic window for cancer therapies such as T-cell bispecific antibodies, CAR-T and ADCs (Antibody Drug Conjugates). Preclinical data show GO’s approach can provide superior specificity in targeting solid tumors over normal tissue, and demonstrate clean in-vivo toxicity profiles in the context of potent immunotherapies.”

Roche is expected to begin clinical trials on the licensed drug candidate in 2020, with GO starting clinical trials on its own drug candidate next year. GO is also developing a pipeline of other antibodies targeted against lymphomas, glioblastomas, liver, kidney and lung cancer tumors.

References

  1. http://gotherapeutics.com/2018/10/go-therapeutics-enters-into-a-license-agreement-with-roche-for-new-glycotargeting-bispecific-cancer-treatment/
  2. https://www.bizjournals.com/boston/news/2018/10/02/cancer-startup-go-therapeutics-eyes-clinic-after.html

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
JPM 2024: Biotech Companies Mapping Out Their Future, and a New Round of M&A Spree Begins
2024-01-09
Flow Cytometry-based Immunophenotyping for Quantifying Human Immunity and Promoting Precision Health
2024-01-08
LATEST
Eli Lilly Breaks Records with $9B Total Investment in Indiana Weight-loss Drug Expansion
2024-05-27
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
2024-05-24
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
2024-05-23
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
2024-05-23
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
2024-05-22
GV Announces Cooperation with CICC
2024-05-22
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
2024-05-22
EVENT
Scroll to Top